Page last updated: 2024-11-07

gamma-hydroxy-gamma-ethyl-gamma-phenylbutyramide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID128930
SCHEMBL ID5898545
MeSH IDM0073994

Synonyms (21)

Synonym
4-hydroxy-4-phenylhexanamide
benzenebutanamide, gamma-ethyl-gamma-hydroxy-, (+-)-
4-hydroxy-4-phenylcaproamide
4-hphm
gamma-ethyl-gamma-hydroxybenzenebutanamide
gamma-hydroxy-gamma-ethyl-gamma-phenylbutyramide
4-hydroxy-4-ethyl-4-phenylbutyramide
benzenebutanamide, gamma-ethyl-gamma-hydroxy-
hphca
76425-98-4
67880-30-2
unii-ml6o5cfj3j
ml6o5cfj3j ,
SCHEMBL5898545
dl-4-hydroxy-4-phenylhexanamide
4-hydroxy-4-phenylcaproamide, (+/-)-
benzenebutanamide, .gamma.-ethyl-.gamma.-hydroxy-
.gamma.-hydroxy-.gamma.-ethyl-.gamma.-phenylbutyramide
DTXSID20987243
4-hydroxy-4-phenylhexanimidic acid
Q27284101

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" According to the proportion of different kinds of HepB vaccines distributed, the annual administration data of the most distributed HepB produced by Bio-Kangtai and its corresponding adverse reaction reports were collected and analyzed."( Change in adverse event reporting following immunization of hepatitis B vaccine among infants between 2013 to 2020 before and after the vaccine administration law in China.
Black, S; Cui, F; Huang, N; Liang, X; Lu, QB; Wang, C, 2022
)
0.72
" Hepatitis B vaccination is a safe and effective means of preventing the complications of hepatitis B disease and continuous standardized AEFI investigation and assessment of causal association should be maintained."( Change in adverse event reporting following immunization of hepatitis B vaccine among infants between 2013 to 2020 before and after the vaccine administration law in China.
Black, S; Cui, F; Huang, N; Liang, X; Lu, QB; Wang, C, 2022
)
0.72
" Adverse events (AEs) were collected on Days 1-14 following each vaccination."( Safety, tolerability, and immunogenicity of V114 pneumococcal vaccine compared with PCV13 in a 2+1 regimen in healthy infants: A phase III study (PNEU-PED-EU-2).
Banniettis, N; Benfield, T; Bickham, K; Churchill, C; Dagan, R; Kaminski, J; Lupinacci, R; McFetridge, R; Mercer, S; Musey, L; Park, J; Rämet, M; Richmond, P; Seppä, I; Valentini, P; Wittke, F, 2023
)
0.91

Dosage Studied

ExcerptRelevanceReference
" Optimal HepB-CpG dosing deserves further study."( A real world comparison of HepB (Engerix-B®) and HepB-CpG (Heplisav-B®) vaccine seroprotection in patients receiving maintenance dialysis.
Aweh, G; Frament, J; Lacson, EK; Ladik, V; Manley, HJ, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (32)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (9.38)18.7374
1990's4 (12.50)18.2507
2000's1 (3.13)29.6817
2010's2 (6.25)24.3611
2020's22 (68.75)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.49

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.49 (24.57)
Research Supply Index3.61 (2.92)
Research Growth Index6.10 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.49)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (9.09%)5.53%
Reviews2 (6.06%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other28 (84.85%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]